
## **Stanley Shaldon**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10986930/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. Kidney International, 1990, 37, 85-93.	5.2	187
2	Permeability of dialyzer membranes to TNFα-inducing substances derived from water bacteria. Kidney International, 1992, 42, 61-68.	5.2	144
3	Detection of endotoxin-like interleukin-1-inducing activity during in vitro dialysis. Kidney International, 1988, 33, 29-35.	5.2	138
4	Portal hypertension in the myeloproliferative syndrome and the reticuloses. American Journal of Medicine, 1962, 32, 758-764.	1.5	116
5	THE USE OF VASOPRESSIN ('PITRESSIN') IN THE CONTROL OF BLEEDING FROM Å'SOPHAGEAL VARICES. Lancet, The, 1960, 276, 222-225.	13.7	109
6	Gene expression of interleukin- $1\hat{l}^2$ during hemodialysis. Kidney International, 1993, 43, 712-721.	5.2	105
7	Hemodynamic changes during sequential ultrafiltration and dialysis. Kidney International, 1979, 15, 411-418.	5.2	91
8	Effect of Pitressin on the Splanchnic Circulation in Man. Circulation, 1961, 24, 797-807.	1.6	79
9	Plasma Interleukin-1 Activity during Hemodialysis: The Influence of Dialysis Membranes. Nephron, 1988, 50, 273-276.	1.8	68
10	Imaging of dialysis-related amyloid (AB-amyloid) deposits with 1311-β2-microglobulin. Kidney International, 1990, 38, 1169-1176.	5.2	54
11	Use of Internal Arteriovenous Fistula in Home Haemodialysis. BMJ: British Medical Journal, 1968, 4, 671-673.	2.3	33
12	Impaired endotoxin-induced interleukin-1β secretion, not total production, of mononuclear cells from ESRD patients. Kidney International, 1995, 47, 1158-1167.	5.2	18
13	Recombinant versus natural human 1111n-β2-microglobulin for scintigraphic detection of Aβ2m amyloid in dialysis patients. Kidney International, 2000, 58, 873-880.	5.2	17
14	Beyond The Current Paradigm: Recent Advances in The Understanding of Sodium Handling – Guest Editors: Stanley Shaldon and Joerg Vienken: Salt, the Neglected Silent Killer. Seminars in Dialysis, 2009, 22, 264-266.	1.3	15
15	Biological Consequences of Monocyte Activation during Hemodialysis. Contributions To Nephrology, 1987, 59, 1-9.	1.1	9
16	Haemodialysis Monitors and Monitoring. , 1983, , 223-241.		8
17	The Interleukin Hypothesis: A Reappraisal after 6 Years. Seminars in Dialysis, 1989, 2, 172-175.	1.3	7
18	Biocompatibility in Hemodialysis: Clinical Relevance in 1995. Artificial Organs, 1995, 19, 395-397.	1.9	5

STANLEY SHALDON

#	Article	IF	CITATIONS
19	From Isolated Ultrafiltration to Blood-Temperature-Controlled Feedback: An Odyssey Started by Jonas Bergström. Blood Purification, 2006, 24, 218-221.	1.8	5
20	Opinion: What Clinical Insights from the Early Days of Dialysis Are Being Overlooked Today?. Seminars in Dialysis, 2005, 18, 18-19.	1.3	4
21	Salt restriction and not length of dialysis is the key to drug free blood pressure control in ESRD patients. Journal of Nephrology, 2003, 16, 159.	2.0	3
22	Beyond The Current Paradigm: Recent Advances in The Understanding of Sodium Handling – Guest Editors: Stanley Shaldon and Joerg Vienken: An Introduction. Seminars in Dialysis, 2009, 22, 252-252.	1.3	2
23	Monitoring of unattended overnight hemodialysis in the home. Hemodialysis International, 2005, 9, 68-69.	0.9	1
24	Biocompatibility — Clinical Aspects. , 1996, , 734-749.		1
25	Should Cuprophane Membranes Continue to Be Used for Chronic Hemodialysis?. Seminars in Dialysis, 1992, 5, 112-113.	1.3	Ο
26	The interleukin hypothesis. Journal of Japanese Society for Dialysis Therapy, 1988, 21, 1085-1089.	0.0	0